Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER versus CEFUROXIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER versus CEFUROXIME.
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER vs CEFUROXIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has bactericidal activity against a broad range of gram-positive and gram-negative bacteria.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking and leading to cell lysis.
1-2 g intravenously or intramuscularly every 24 hours. Maximum dose: 4 g daily.
250-500 mg orally twice daily; 750 mg-1.5 g IV/IM every 8 hours for moderate infections; 1.5 g IV/IM every 8 hours for severe infections.
None Documented
None Documented
Clinical Note
moderateCefuroxime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefuroxime."
Clinical Note
moderateCefuroxime + Cimetidine
"Cefuroxime can cause a decrease in the absorption of Cimetidine resulting in a reduced serum concentration and potentially a decrease in efficacy."
Clinical Note
moderateCefuroxime + Methantheline
"Cefuroxime can cause a decrease in the absorption of Methantheline resulting in a reduced serum concentration and potentially a decrease in efficacy."
Clinical Note
moderateTerminal elimination half-life is approximately 5.8-8.7 hours in adults, prolonged to 12-24 hours in elderly, and up to 30-72 hours in neonates. No dose adjustment in renal impairment alone; adjust in severe hepatic impairment.
Terminal elimination half-life is 1.2 hours in adults with normal renal function (increased to 15-22 hours in severe renal impairment [CrCl <10 mL/min], requiring dose adjustment).
Renal (33-67% unchanged) and biliary (up to 40% as unchanged drug and microbiologically inactive metabolites); fecal elimination of unabsorbed drug is minimal. Dose adjustment required in combined renal and hepatic impairment.
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration and tubular secretion; biliary/fecal excretion is minimal (<10%).
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
Cefuroxime + Olanzapine
"Cefuroxime can cause a decrease in the absorption of Olanzapine resulting in a reduced serum concentration and potentially a decrease in efficacy."